Microtome Market Assessment, By Product Type [Microtome Instruments, Microtome Accessories], By Technology Type [Manual Microtomes, Semi-Automated Microtomes, Full-Automated Microtomes], By Application Type [Disease Diagnosis, Medical Research], By End-us

Microtome Market Assessment, By Product Type [Microtome Instruments, Microtome Accessories], By Technology Type [Manual Microtomes, Semi-Automated Microtomes, Full-Automated Microtomes], By Application Type [Disease Diagnosis, Medical Research], By End-user [Hospital Laboratories, Clinical Laboratories, Others], By Region, Opportunities and Forecast, 2017-2031F

Global microtome market is projected to witness a CAGR of 5.8% during the forecast period 2024-2031F, growing from USD 175.4 million in 2023 to USD 275.37 million in 2031F. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.

Microtomes are highly advanced precision-based tools involved in slicing or sectioning biological specimens into very thin slices to examine or study them. Microtomes are essential in histology, pathology, or clinical research fields. The market for microtomes is anticipated to expand significantly in the upcoming years. The market has the potential to expand due to several factors, including rising research and development, technology advancements, increased prevalence of chronic disorders, and an overall increasing population aware of its health. Additionally, the industry has seen the launch of compact and smart devices that provide faster and more precise medical findings and are helpful in the early detection of any disorders.

Healthy lifestyles are becoming more popular as people become more conscious about them. Industry giants and healthcare practitioners are collaborating to provide the best tools and diagnostic solutions for patients. Both public and commercial organizations are raising money and investing a sizable sum in providing quality solutions. These massive corporations use strategic maneuvers such as collaborations, investments, and mergers and acquisitions when they are striving to develop or introduce a new product.

For instance, the Georgetown Public Hospital Corporation (GPHC) recently announced the procurement of auto tissue processors and microtome machines, which has resulted in a substantial development in the Pathology Department. The department has revolutionized sample processing with these two technologies, cutting the turnaround time from over thirty (30) days to an astounding seven days.

Technological Advancements in Microtomes

Microtomes are special instruments that help with tissue sectioning while being accurate and consistent, eliminating the possibility of human error and greatly increasing process speed and efficiency. There is a serious need for automated microtomes, especially in high-throughput research institutions and laboratories. Digital technology has revolutionized microtome systems through its integration with AI. As the tissue sections are sliced, high-resolution photographs of the sections are captured by the imaging sensors and software which are built into digital microtomes.

In addition to giving an instant visual record of the samples, digital analysis, and 3D reconstruction made easy, it facilitates the identification of abnormalities, supports better performance of quantitative evaluations, and makes sharing of results with associates and colleagues easier. Highly specialised blade materials, such as tungsten carbide and diamond, have been used because of technological advancements, ensuring accurate and reliable sectioning. These materials have improved the quality of the sections produced, elongate the life of the blade, and decreased the frequency of blade replacements which saves both time and money.

The market for microtomes has seen the introduction of Al and ML technologies, especially in digital microtomes. Algorithms can be utilized by these systems to identify and distinguish between different tissue architectures, optimize cutting parameters, and offer automated input regarding the upkeep and replacement of blades. These features simplify the tissue sectioning procedure, minimizing the need for human intervention, and raise the microtome's overall effectiveness. Manufacturers of microtome devices are able to provide remote monitoring and diagnostics due to its introduction to the Internet of Things (IoT). It minimizes downtime and guarantees optimal instrument performance by enabling customers to monitor the performance of their microtomes in real-time, receive maintenance alerts, and access remote support services. The creation of microtomes with ergonomic designs and user-friendly interfaces is the result of technological breakthroughs. These upgrades make the instruments more user-friendly, lessen operator fatigue, and provide accessibility for a wider variety of users.

For instance, medical robotics manufacturer Clarapath, Inc. has acquired Crosscope Inc., a medical artificial intelligence (AI) software startup that creates AI-powered telepathology for medical picture information extraction and precision medicine diagnostics, to offer an end-to-end digital pathology solution. According to a Clarapath Inc. press statement, the agreement will allow Crosscope Inc.'s digital pathology platform to be layered atop Clarapath Inc.'s histology automation gear, thereby improving the calibre and effectiveness of diagnostic services for future clients.

Tissue Engineering and Regenerative Medicine

The dynamic field of tissue engineering and regenerative medicine, which is at the forefront of medical research and innovation, is crucial in driving the worldwide microtome market. To create modified tissues and apply regenerative medicine in the field of research, microtomes precision machines used for the sectioning of biological specimens are essential tools. Microtomes are used in tissue engineering to create scaffold structures from biomaterials such as donor tissues. These scaffolds are used as the starting point for the culture or seeding of cells, including stem cells.

By sectioning these scaffolds precisely and consistently, microtomes make it possible to create three-dimensional structures which closely resemble the natural tissues of the human body. These artificial tissues can be used for many different things, such as growing new organs in place of injured or unhealthy ones. Microtomes are essential in the field of regenerative medicine as they facilitate the creation of tissue slices for grafting, transplanting, and other regenerative procedures. This area of study focuses on replacing or repairing damaged or degenerated tissues by utilizing tissue engineering techniques in conjunction with the body's inherent healing powers. The creation of precise-thickness tissue grafts, which is necessary for effective transplant operations, is facilitated by microtomes.

A medical genetics business called Invitae Corp. announced full access to their PCMTM (Personalised Cancer Monitoring) platform in March 2022. The technology helps identify patients with solid tumors who have molecular residual disease (MRD). Based on previous studies, Invitae PCM detects circulating tumour DNA (ctDNA) in blood using a unique set of personalized tests based on a patient's tumor. It allows for risk stratification, treatment response assessment, and cancer recurrence identification.

Increasing Demand for Rotary Microtomes

Among different microtomes, rotary microtomes are generally considered to be superior. The dominance in the global market is fueled by several important aspects. Thin tissue slices are essential for histological and pathological investigation, and this equipment is made to prepare them precisely and effectively. The capacity of rotary microtomes to generate consistently thin and uniform sections is a prerequisite for precise microscopic examination and diagnosis, which is one of its main advantages. With hard or sensitive materials, rotary microtomes' sturdy design and mechanical stability guarantee that there is little no movement or vibration during sectioning, to produce high-quality sections. With other kinds of microtomes, including sliding or vibrating microtomes, such degree of precision is hard to accomplish.

Additionally, rotating microtomes are more adaptable, considering a wider range of specimens to diversify the research in clinical settings. The functionality of rotating microtomes has been substantially improved by technological developments. Digital control panels, programmable settings, automatic sectioning, and other technologies which enhance user ease and reproducibility of findings at standard on modern models. With the reduction of human labor and rise in productivity brought by these improvements, rotary microtomes are the standard in high-throughput laboratories. The rising need for biomedical research and histopathological diagnoses is propelling the growth of the global microtome market.

Rotary microtomes are at the forefront of this growth, which offer better performance, precision, and cutting-edge features. Their dominant position in the microtome market is backed by features that can handle the demanding standards of contemporary histology laboratories. For instance, Precisionary launched the manual rotary microtome model RF-600 which is perfect for routine tissue sectioning in histology. For a reasonable price, microtome offers steadiness and extremely precise cutting. Users receive tissue sections that are high-quality, repeatable, and embedded in paraffin wax with this model.

North America to Dominate Global Microtome Market

With the biggest market share, North America became the leading force in the worldwide microtome market. North America has one of the world's most sophisticated and advanced healthcare infrastructures. Modern hospitals, research centres, and diagnostic labs in the area mostly depend on microtomes for precise tissue sectioning in fields such as pathology, histology, and research. These facilities create a significant need for microtome technology. Chronic illnesses such as cancer, heart disease, and neurological disorders are comparatively common in North America. For instance, the Canadian Cancer Society's 2022 figures show that around 233,900 cancer cases were diagnosed in Canada in 2022.For patient care and public health, accurate diagnosis and research are essential in these fields. Microtomes are essential tools for early disease identification and characterization when preparing tissue samples for histopathological investigation. For instance, Myriad Genetics, Inc. launched studies and expansion of precise oncology solutions portfolio in 2023 at the American Society of Clinical Oncology. It shows the rising need for microtomes as they are essential in research. Such innovations and research ensure the market expansion of global microtome market.

Future Market Scenario (2024 – 2031F)

One of the main factors contributing to the anticipated growth of global microtome market is the increasing research and development in medicine and diagnostics. Given that technology is advancing, we can expect cutting-edge technology in the region. Players in the market are expanding at an unparalleled rate, introducing cost-effective and efficient technologies. For instance, Eli Lilly and Company and F. Hoffmann-La Roche Ltd. (Roche) develops drugs and diagnostics to treat major diseases. They announced on March 22, 2023, that they have partnered to support the development of Roche's Elecsys Microtomes.

Key Players Landscape and Outlook

Several companies are expanding business by planning and adopting new strategies. They are complying with new strategic initiatives regarding the launches of newly developed microtomes to help researchers and bring up their market presence. New product launches, agreements based on contracts, acquisitions and mergers, and investments and partnerships are a few ways to grow.

In a partnership with Creaky Joints, a leading provider of support, education, advocacy, and research for people living with arthritis and rheumatic disease, it was announced in May 2022 by United Rheumatology, a rheumatology care management organization that enables rheumatologists to advance the standard of care and to develop the Cancer Wellness Center, a digital resource designed to assist those living with cancer.

The FDA approved Myriad Genetics Inc.'s BRACAnalysis CDx histology test in March 2022 for use as a companion diagnostic to identify patients with germline BRCA-mutated (gRBCAm) HER2 negative, high-risk early-stage breast cancer may benefit from Lynparza. Myriad Genetics, Inc. is a precision medicine and genetic testing company in the United States.